NHS Greater Glasgow & Clyde Area Drug and Therapeutics Committee
Greater Glasgow and Clyde Medicines
Medicines Update

Melatonin Shared Care Agreement for use in children

The Shared Care Agreement (SCA) for melatonin use in children with sleep disturbance has been reviewed and updated to reflect a change in preferred product, with a move away from Bio-melatonin® tablets as a result of recent national effective prescribing cost efficiency recommendations. Formulary products included in the SCA are immediate release 3mg capsules (preferred), Circadin® 2mg SR tablets and melatonin 1mg/ml liquid (available as a ‘special’). Solid dose formulations are suitable for the majority of patients. More details of the licensing status of these medicines can be found in the SCA.


These products allow a variety of doses to be prescribed and can be used in combination to achieve the total daily dose. It is not uncommon to find immediate and sustained release formulations co-prescribed as the combination addresses issues with sleep onset and sleep latency. The immediate release capsules can also be opened and sprinkled on foodstuff where required.

 

Published 22/11/17